MoonLake Immunotherapeutics
Latest round
- Series A
Last raised
- May 2021
Total raised
- Undisclosed
Investors
- 2
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics AG specializes in creating advanced treatments targeting inflammatory conditions. The company was founded in 2021 by Arnout Van Amstel, Jorge Da Silva, and Kristian Reich, with Jorge Da Silva currently serving as CEO.00 mn. Moonlake Immunotherapeutics specializes in the development of innovative therapeutic solutions targeting inflammatory diseases. Their core product, Sonelokimab, is a Nanobody® designed to address conditions such as hidradenitis suppurativa, psoriatic arthritis, psoriasis, and ankylosing spondylitis. These treatments aim to alleviate the severe impact of these long-term conditions on patients' quality of life. Moonlake actively sponsors and conducts clinical trials globally, particularly focusing on Phase 2 and Phase 3 programs for Sonelokimab, which are being rolled out in various regions, including Europe and North America.Moonlake Immunotherapeutics generates revenue through partnerships and collaborations with healthcare institutions and research organizations, focusing on clinical trial advancements and product development. The company's business model involves direct agreements with healthcare providers for the distribution of Sonelokimab once approved for commercial use. Future growth strategies may include introducing new products and expanding into markets across Europe and North America, aligning with ongoing clinical trials and regulatory efforts.
Who invested in MoonLake Immunotherapeutics
2 investors across 1 round
See all investors in MoonLake Immunotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 3, 2021
Amount
Undisclosed
Investors
Questions about MoonLake Immunotherapeutics
Who invested in MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MoonLake Immunotherapeutics raised?
MoonLake Immunotherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did MoonLake Immunotherapeutics last raise money?
MoonLake Immunotherapeutics's most recent round on record is a Series A, in May 2021.
What does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics AG specializes in creating advanced treatments targeting inflammatory conditions.
Where is MoonLake Immunotherapeutics headquartered?
MoonLake Immunotherapeutics is headquartered in Zug, Switzerland.
Which VCs invest in companies like MoonLake Immunotherapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at MoonLake Immunotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like MoonLake Immunotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.